H1 2021 revenue growth of 14.7 % for Theranostics Theranostics activity up 33.6% in the United States Good performance for IVD, with growth of 10.4% Croissy-Beaubourg, July 19, 2021, 7.30 am CEST – THERADIAG…
Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces that the Extraordinary General Meeting…
Croissy-Beaubourg, May 31, 2021, 5:45 pm CEST – THERADIAG (ISIN: FR0004197747, Ticker: ALTER, eligible for PEA-PME equity savings plans), a company specializing in in vitro diagnostics and theranostics, announces the launch of HUMABDIAG, a large-scale…